Indeed, SIRT3 seems to mitigate diabetic cardiomyopathy by deacetylating the transcription factor p53, consequently decreasing the expression of the fructose‐2,6‐bisphosphatase TP53‐induced glycolysis and apoptosis regulator (TIGAR).115. The gene discussed is TP53; the disease is diabetic cardiomyopathy.